Literature DB >> 11685975

Prolonged duration of response to infliximab in early pediatric Crohn's disease.

S Kugathasan1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11685975     DOI: 10.1097/00005176-200109001-00007

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


× No keyword cloud information.
  4 in total

1.  Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn' disease.

Authors:  N A Afzal; A Ozzard; S Keady; M Thomson; S Murch; R Heuschkel
Journal:  Dig Dis Sci       Date:  2007-09-05       Impact factor: 3.199

Review 2.  Use of the tumor necrosis factor-blockers for Crohn's disease.

Authors:  Alan B R Thomson; Milli Gupta; Hugh J Freeman
Journal:  World J Gastroenterol       Date:  2012-09-21       Impact factor: 5.742

Review 3.  Infliximab therapy in children and adolescents with inflammatory bowel disease.

Authors:  Gabor Veres; Robert N Baldassano; Petar Mamula
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Influence of previous corticosteroid treatment on the efficacy and safety of infliximab therapy in Crohn disease.

Authors:  Ailing Liu; Yue Li; Hong Yang; Hong Lv; Jiaming Qian
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.